Important Safety Information - Wegovy® Pill

Important Safety Information — Wegovy® Pill (oral semaglutide tablets)

This summary is drawn from the FDA-approved Prescribing Information for Wegovy® (semaglutide), revised February 2026. It does not replace the full Prescribing Information and Medication Guide. Review the complete Prescribing Information before starting treatment.

The Wegovy® Pill contains semaglutide, the same active ingredient used in the injectable form of Wegovy®. The method of administration differs (oral tablet vs. injection), but the safety profile, boxed warning, and contraindications are based on semaglutide itself.

Boxed Warning: Risk of Thyroid C-Cell Tumors
In studies in rodents, semaglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether semaglutide causes thyroid C-cell tumors, including MTC, in humans, because the human relevance of these rodent findings has not been determined.

Do not use the Wegovy® Pill if:

  • You or any family member has ever had medullary thyroid carcinoma (MTC), or
  • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Tell your provider right away if you notice any of these symptoms of a possible thyroid tumor:

  • A lump or swelling in the neck
  • Hoarseness that does not go away
  • Trouble swallowing
  • Shortness of breath

What the Wegovy® Pill Is Used For
The Wegovy® Pill is a prescription medicine used along with a reduced-calorie diet and increased physical activity in adults to:

  • Reduce excess body weight and help maintain weight reduction long term in adults with obesity (BMI ≥ 30 kg/m²), or in adults with overweight (BMI ≥ 27 kg/m²) who also have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol); and
  • Reduce the risk of major cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight.

It is not known whether the Wegovy® Pill is safe and effective in people under 18 years of age.

Who Should Not Use the Wegovy® Pill
Do not use the Wegovy® Pill if you:

  • Have a personal or family history of medullary thyroid carcinoma (MTC);
  • Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); or
  • Have had a serious allergic reaction to semaglutide or any of the ingredients in the Wegovy® Pill.

Do not use the Wegovy® Pill together with other semaglutide-containing products or any other GLP-1 receptor agonist medicine.

Before Taking the Wegovy® Pill, Tell Your Provider If You

  • Have type 1 or type 2 diabetes;
  • Have a history of pancreatitis;
  • Have kidney problems;
  • Have a history of diabetic retinopathy;
  • Have severe problems with your stomach emptying (severe gastroparesis);
  • Have ever had a serious allergic reaction (such as anaphylaxis or angioedema) to a GLP-1 medicine; or
  • Are pregnant, planning to become pregnant, or breastfeeding.

Give your provider a complete and accurate medical history. Leaving out relevant information could lead to serious harm.

Pregnancy and Reproductive Planning

  • The Wegovy® Pill should not be used during pregnancy. Weight loss offers no benefit during pregnancy and may harm an unborn baby.
  • If you become pregnant while taking the Wegovy® Pill, stop taking it and tell your provider.
  • Because semaglutide stays in the body for a long time, stop the Wegovy® Pill at least 2 months before a planned pregnancy.
  • Breastfeeding is not recommended while taking the Wegovy® Pill.

A pregnancy registry monitors outcomes in women exposed to semaglutide during pregnancy. If you become pregnant while taking the Wegovy® Pill, you and your provider are encouraged to report the pregnancy to the Novo Nordisk pregnancy registry at 1-877-390-2760 or www.wegovypregnancyregistry.com.

Drug Interactions
The Wegovy® Pill slows stomach emptying, which can affect how other oral medications are absorbed. Use caution with oral medicines that have a narrow margin of safety or that require monitoring, and tell your provider about all the medicines you take, including:

  • Insulin or insulin secretagogues (such as sulfonylureas), which can raise the risk of low blood sugar when combined with the Wegovy® Pill;
  • Other GLP-1 receptor agonist or semaglutide-containing medicines;
  • Other weight-loss products; and
  • All prescription and over-the-counter medicines, vitamins, and supplements.


Serious Side Effects
Seek medical attention right away if you have symptoms of any of the following:

  • Thyroid tumors — a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
  • Inflammation of the pancreas (pancreatitis) — severe and persistent abdominal pain that may spread to the back, with or without nausea or vomiting.
  • Gallbladder problems — upper-stomach pain, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.
  • Low blood sugar (hypoglycemia) — especially if you also take insulin or a sulfonylurea. Know the signs (dizziness, shakiness, sweating, confusion).
  • Kidney problems (acute kidney injury) — particularly if nausea, vomiting, or diarrhea leads to dehydration.
  • Serious allergic reactions — swelling of the face, lips, tongue, or throat, or trouble breathing.
  • Diabetic retinopathy complications — vision changes, particularly in people with type 2 diabetes.
  • Increased heart rate.
  • Risk during anesthesia or deep sedation — because the medicine slows stomach emptying, food may remain in the stomach. Tell your surgical or procedure team that you take the Wegovy® Pill ahead of any planned surgery or procedure.


Most Common Side Effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal (stomach) pain
  • Headache
  • Fatigue
  • Indigestion (dyspepsia)
  • Dizziness
  • Abdominal bloating
  • Belching
  • Gas (flatulence)
  • Low blood sugar (hypoglycemia) in people with type 2 diabetes
  • Stomach flu (gastroenteritis)
  • Acid reflux (GERD)
  • Common cold symptoms (nasopharyngitis)


Side effects are most common during dose escalation.

How the Wegovy® Pill Is Taken

  • Take one tablet by mouth once daily, in the morning, on an empty stomach, with no more than 4 ounces of plain water. Do not take it with any other liquids.
  • Swallow the tablet whole. Do not split, crush, chew, or dissolve it.
  • After taking it, wait at least 30 minutes before eating food, drinking other beverages, or taking other oral medications.
  • The starting dose is 1.5 mg once daily, increased gradually under your provider's guidance (typically 4 mg, then 9 mg, then a 25 mg maintenance dose), about every 30 days, to help reduce gastrointestinal side effects.
  • Take only one tablet per day. If you miss a dose, skip it and take your next dose the following day.
  • Do not change your dose without speaking to your provider.


Additional Safety Notes

  • Do not combine the Wegovy® Pill with other GLP-1 receptor agonist medicines.
  • Do not adjust your dose on your own.
  • Follow your provider's titration and administration instructions carefully.


Reporting Side Effects
You are encouraged to report side effects of prescription drugs:


This summary does not replace the full Prescribing Information and Medication Guide. Review the complete Prescribing Information before initiating treatment.

Wegovy® is a registered trademark of Novo Nordisk. Naky Health LLC is not affiliated with, endorsed by, or sponsored by Novo Nordisk, and does not manufacture these medications. All referenced medications are FDA-approved prescription drugs available only when prescribed by a licensed healthcare provider. Individual eligibility, including eligibility for any specific medication or formulation, is determined at the sole discretion of your provider. Naky Health LLC does not guarantee access to any specific medication.